QURE - Uniqure NV
Uniqure NV Logo

QURE - Uniqure NV

https://www.uniqure.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.

52W High
$19.18
52W Low
$4.45
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.13
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
27.93
EV/EBITDA (<8 favorable)
0.99
EV/Revenue (<3 favorable)
47.05
P/S (TTM) (<3 favorable)
68.69
P/B (<3 favorable)
2.83
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
6.08%
Institutions (25–75% balanced)
96.91%
Shares Outstanding
54,867,000
Float
38,737,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
14,337,000
Gross Profit (TTM)
-121,873,000
EPS (TTM)
-3.90
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-7.91%
ROE (TTM) (>15% strong)
-4.28%
EPS YoY (Quarterly) (>10% good)
-0.18
Revenue YoY (Quarterly) (>8% good)
-0.53
Momentum
Bearish momentum
Value
0.7174
Previous
0.8412
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025